<DOC>
	<DOCNO>NCT00986284</DOCNO>
	<brief_summary>This study aim investigate efficacy safety gefitinib neoadjuvant therapy stage IIIA NSCLC patient .</brief_summary>
	<brief_title>Epidermal Growth Factor Receptor ( EGFR ) Status Based Gefitinib Neoadjuvant Therapy Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Patients pathological diagnose NSCLC , EGFR sensitive mutation ; Stage IIIA patient technical operable disease evaluate image lab result ; Patients without chemotherapy targetedtherapy ; Inform Consent . Patients malignant tumor lung cancer ; Patients diseases cardiovascular disease may hamper follow ; Patients may coordinate well , judge researcher .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>Neoadjuvant Therapy</keyword>
</DOC>